aTYR PHARMA INC financial data

Symbol
ATYR on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
10240 Sorrento Valley Road, Suite 300, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 607 % -24.4%
Return On Equity -85.2 % -70.9%
Return On Assets -62.8 % -60.6%
Operating Margin -28.9K % -85.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 88.9M shares +31.2%
Common Stock, Shares, Outstanding 84M shares +32.8%
Entity Public Float 116M USD -3.75%
Common Stock, Value, Issued 84K USD +33.3%
Weighted Average Number of Shares Outstanding, Basic 74.3M shares +38.5%
Weighted Average Number of Shares Outstanding, Diluted 74.3M shares +38.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 235K USD -33.4%
Research and Development Expense 54.4M USD +28.6%
General and Administrative Expense 13.8M USD +6.15%
Operating Income (Loss) -67.9M USD -23.7%
Nonoperating Income (Expense) 3.89M USD -13.9%
Net Income (Loss) Attributable to Parent -64M USD -27.1%
Earnings Per Share, Basic -0.86 USD/shares +8.51%
Earnings Per Share, Diluted -0.86 USD/shares +8.51%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 11.1M USD -51%
Assets, Current 82M USD -20.4%
Property, Plant and Equipment, Net 4.85M USD -12.3%
Operating Lease, Right-of-Use Asset 5.82M USD -13.5%
Other Assets, Noncurrent 66K USD -49.6%
Assets 96.8M USD -19.7%
Accounts Payable, Current 4.32M USD +22.5%
Employee-related Liabilities, Current 3.09M USD +14.3%
Accrued Liabilities, Current 9.39M USD -18.7%
Liabilities, Current 15M USD -8.83%
Operating Lease, Liability, Noncurrent 11.1M USD -9.69%
Accumulated Other Comprehensive Income (Loss), Net of Tax -40K USD +45.9%
Retained Earnings (Accumulated Deficit) -532M USD -13.7%
Stockholders' Equity Attributable to Parent 70M USD -22.8%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 69.8M USD -22.8%
Liabilities and Equity 96.8M USD -19.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -22.4M USD -3693%
Net Cash Provided by (Used in) Financing Activities 7.73M USD -84.4%
Net Cash Provided by (Used in) Investing Activities -1.36M USD +96.4%
Common Stock, Shares Authorized 170M shares 0%
Common Stock, Shares, Issued 84M shares +32.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -16M USD -249%
Interest Paid, Excluding Capitalized Interest, Operating Activities 38K USD -17.4%
Deferred Tax Assets, Valuation Allowance 124M USD +15%
Deferred Tax Assets, Gross 125M USD +14.6%
Operating Lease, Liability 11.9M USD -12%
Payments to Acquire Property, Plant, and Equipment 17K USD -98.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -64M USD -27.9%
Property, Plant and Equipment, Gross 9.39M USD -7.49%
Operating Lease, Liability, Current 711K USD -14.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.78M USD -9.87%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.72M USD -11.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 5.64M USD -12.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.92M USD -0.36%
Deferred Tax Assets, Operating Loss Carryforwards 68.8M USD +14.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 36.8M USD +22.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.98M USD +1.7%
Additional Paid in Capital 602M USD +7.76%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 178K USD +123%
Deferred Tax Assets, Net of Valuation Allowance 1.22M USD -13.5%
Share-based Payment Arrangement, Expense 2.99M USD +15%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%